Evaluating survival factors in patients with Extranodal NK/T-cell Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess prognostic factors affecting overall survival and progression-free survival in patients diagnosed with Extranodal NK/T-cell Lymphoma (ENKTL). It utilizes a retrospective cohort design, analyzing anonymized patient data collected from January 1, 2000, to August 31, 2020. The study will establish a prognostic predictive nomogram to aid in predicting outcomes for ENKTL patients based on their clinical characteristics. Pathological reviews of initial diagnoses will be conducted by designated pathologists to ensure accuracy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients newly diagnosed with ENKTL
* Patients diagnosed between January 1, 2000 and August 31, 2020
* Patients older than 18 years

Exclusion Criteria:

* Patients who did not have complete clinical information or immunohistochemistry, or who were lost follow-up immediately after treatment.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Hua Wang — Sun Yat-sen University
• Study coordinator: Hua Wang
• Email: wanghua@sysucc.org.cn
• Phone: +862087342462

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Epstein-Barr virus–positive T/NK-cell lymphoproliferative diseases in large patient groups

  This study follows patients with EBV-positive T/NK-cell disorders to see how they present, what treatments are used, and how they respond over time.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07727083

• Frontline immunotherapy versus chemotherapy induction for advanced Extranodal NK/T-cell lymphoma, followed by autologous stem cell transplant

  This study tests whether starting with immunotherapy plus targeted drugs is more effective than standard chemotherapy to help patients with advanced extranodal NK/T‑cell lymphoma, then all patients who reach a strict remission proceed to autologous stem cell transplantation.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07678229

• Tislelizumab plus Zeprumetostat in relapsed or refractory NK/T-cell lymphoma

  This study tests whether combining tislelizumab with zeprumetostat can help patients with relapsed or refractory NK/T-cell lymphoma after prior chemotherapy.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT07502768

• Treatment for untreated extranodal NK/T-cell lymphoma using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people with untreated extranodal NK/T-cell lymphoma feel better and improve their chances of survival.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06824883

• Registry for individuals with T-cell lymphoma

  This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.

  Recruiting at 6 sites Memorial Sloan Kettering Cancer Center · Duarte, California and 25 other locations · NCT05978141

• Evaluating DR-01 for treating specific types of lymphomas

  This study is testing a new treatment called DR-01 to see if it can safely help adults with certain types of lymphomas feel better and fight their cancer.

  Recruiting at 36 sites Phase 1/2 Dren Bio · Birmingham, Alabama and 36 other locations · NCT05475925

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.